

Research Article

The Systematic Analyses of RING Finger Gene Signature for Predicting the Prognosis of Patients with Hepatocellular Carcinoma

Chunfeng Zhang,¹ Yang Yang,² Kun Wang,² Muhua Chen,² Min Lu,³ Chenyu Hu,² Xiaojuan Du,⁴ Baocai Xing,² and Xiaofeng Liu²

¹Department of Medical Genetics, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China

²Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Hepatopancreatobiliary Surgery Department I, Peking University Cancer Hospital & Institute, Beijing 100142, China

³Department of Pathology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China

⁴Department of Cell Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China

Correspondence should be addressed to Xiaofeng Liu; liuxiaofeng100@bjmu.edu.cn

Received 28 October 2021; Accepted 8 September 2022; Published 26 September 2022

Academic Editor: Junmin Zhang

Copyright © 2022 Chunfeng Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

RING finger (RNF) proteins are frequently dysregulated in human malignancies and are tightly associated with tumorigenesis. However, the expression profiles of RNF genes in hepatocellular carcinoma (HCC) and their relations with prognosis remain undetermined. Here, we aimed at constructing a prognostic model according to RNF genes for forecasting the outcomes of HCC patients using the data from The Cancer Genome Atlas (TCGA) program. We collected HCC datasets to validate the values of our model in predicting prognosis of HCC patients from International Cancer Genome Consortium (ICGC) platform. Then, functional experiments were carried out to explore the roles of the representative RNF in HCC progression. A total of 107 differentially expressed RNFs were obtained between TCGA-HCC tumor and normal tissues. After comprehensive evaluation, a prognostic signature composed of 11 RNFs (RNF220, RNF25, TRIM25, BMI1, RNF216P1, RNF115, RNF2, TRAIIP, RNF157, RNF145, and RNF19B) was constructed based on TCGA cohort. Then, the Kaplan-Meier (KM) curves and the receiver operating characteristic curve (ROC) were employed to evaluate predictive power of the prognostic model in testing cohort (TCGA) and validation cohort (ICGC). The KM and ROC curves illustrated the good predictive power in testing and validation cohort. The areas under the ROC curve are 0.77 and 0.76 in these two cohorts, respectively. Among the prognostic signature genes, BMI1 was selected as a representative for functional study. We found that BMI1 protein level was significantly upregulated in HCC tissues. Moreover, the inhibitor of BMI1, PTC-209, displayed an excellent anti-HCC effect *in vitro*. Enrichment analysis of BMI1 downstream targets showed that BMI1 might be involved in tumor immunotherapy. Together, our overall analyses revealed that the 11-RNFs prognostic signature might provide us latent chances for evaluating HCC prognosis and developing novel HCC therapy.

1. Introduction

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. HCC resulted in approximately 781,000 deaths worldwide in 2018, ranking as the fourth leading cause of cancer-related death according to the assess-

ment by GLOBOCAN [1, 2]. Despite a series of treatment strategies for HCC have been developed, the overall outcome of HCC patients is poor. In the current, the optimal therapy is curative resection for HCC at early stage, while lots of cases are diagnosed in advanced stage with missing surgical timing [3]. Upon tumor progression, the accumulated somatic DNA

alterations constantly help cancer cells gain malignant behaviors [4, 5]. Due to the wide application of high-throughput sequencing method, researchers gain the chance to globally understand the molecular changes in hepatic cancer cells and establish molecular model for evaluating the status of HCC [6]. It has been found that HCC patients with the same clinical stage own specific molecular subtypes and gene signatures [7]. This further supports the possibility to predict HCC patients' outcomes at molecular level. The establishment of prognosis-related molecular model and the discovery of new therapeutic targets for HCC will be helpful for improving the survival rates of HCC patients.

RING finger (RNF) proteins comprise a large family of proteins which play pivotal roles in protein ubiquitination. Ubiquitination is mainly involved in mediating protein degradation, which in turn regulates cellular activities [8, 9]. It has been reported that ubiquitination participates in lots of intracellular biological processes, such as affecting DNA damage repair, modulating cell metabolism, regulating cell death, and altering therapeutic effect [10]. Ubiquitination is defined as a multistep biochemical reaction, which transfers ubiquitin molecules to the substrates. The indispensable enzymes in this reaction include ubiquitin-activating enzyme (E1), ubiquitin-binding enzyme (E2), and ubiquitin ligase (E3) [11]. Among the enzymes, E3 ligases are responsible for specifically recognizing the substrates and transferring ubiquitin to substrates. In eukaryotes, hundreds of E3 ligases have been identified. Generally, E3s mainly fall into three classes based on the conserved domains for ligase activity, namely HECT, RING finger, and U-box [12]. RNF proteins belong to RING finger E3 harboring RINF finger domain [13]. Dysfunction of RNFs leads to intricate alterations of the transcriptome and proteome in tumor cells, further causing changes in cellular activities, including cell growth, proliferation, apoptosis, migration, and invasion [14, 15]. Increasing number of studies have reported that some RNFs are exceptionally expressed in human cancers and are associated with poor prognosis of patients [16, 17], indicating that the certain RNFs might be latent targets for cancer diagnosis and therapy.

Recent studies have found that some RNF proteins play momentous roles in development and progression of HCC. RNF147, also named TRIM25, enhances the HCC cell survival upon cellular stress by targeting Keap1-Nrf2 pathway [18]. RNF2 promotes ubiquitination of SIK1 in HCC cells and promotes cell growth [19]. The overexpression of RNF40, as an E3 ligase of H2B ubiquitination, indicates poor prognosis of HCC patients [20, 21]. These studies indicate that some RNFs are tightly associated with the progression of HCC. The aberrant expression and function of these RNFs offer us new chances for developing inhibitors of HCC. However, the prognostic roles of RNFs in HCC remain undetermined and this urges us to explore the comprehensive roles of RNF-related genes in HCC.

In the present study, we collected RNA-sequencing data of HCC samples from TCGA and ICGC platforms. After evaluating transcriptomic alterations of RNF genes between HCC and nontumorous tissues, we constructed a risk score model with 11 prognostic RNFs. Moreover, BMI1 was selected as the representative to explore its roles in HCC through functional

experiments. Ultimately, we uncovered an RNF-related signature related to the pathogenesis of HCC, which might be applied as latent prognosis-related biomarkers and drug targets for HCC.

2. Materials and Methods

2.1. Patient Samples and Immunoblot. In total, 18 paired HCC tissues and nontumorous tissues were obtained from the Peking University Cancer Hospital. The study was approved by the ethics committee of the Peking University Cancer Hospital. Western blot was carried out according to the previous reports [22, 23]. Anti-BMI1 antibody (A0211) and Anti- β -actin antibody (AC026-100) were purchased from Abclonal Technology (China). PTC-209 (S7372-PTC-209) was purchased from Selleck Chemicals (USA).

2.2. Cell Culture. HepG2, SMMC-7721, or Huh7 cell lines were purchased from the National Infrastructure of Cell Line Resource (NSTI, China). We cultured cells using DMEM or RPMI 1640 medium added with 10% fetal bovine serum. After passage or indicated treatment, cells were cultured in a humidified chamber in 5% CO₂ at 37°C.

2.3. Cell Proliferation Evaluation. Cell proliferation was analyzed using MTS kit (Promega, USA). Briefly, cells were digested and seeded into the 96-well plate. Then, the drugs were added to the cells as indicated. Cell number was determined for each day by MTS assay according to the manufacturer' protocol.

2.4. Colony Formation Experiment. Colony formation assay was carried out according to previously published protocol [24]. Briefly, cells were treated with the indicated concentrations of PTC-209 and subsequently seeded into 6-well plate. Fourteen days later, the colonies were fixed with paraformaldehyde and stained with 0.1% crystal violet (Beyotime, China). The visible colonies were counted using ImageJ software.

2.5. Data Collection and Analysis. The RNA sequencing data and the related clinical data of HCC were obtained from TCGA website (<https://portal.gdc.cancer.gov/>). The RNF gene set including 227 genes was obtained from GEPIA website [25]. We preprocessed the raw data using Limma package in R software. Then, we collected the RNFs expression profile from LIHC (Liver Hepatocellular Carcinoma) dataset including 374 tumorous and 50 normal samples for the following analyses. The differentially expressed RNFs were identified using the criteria: $|\log_2FC| \geq 1$ and $FDR < 0.05$. The "pheatmap" package was employed for unsupervised clustering analysis in R software. The validation dataset of gene expression and clinical trait data (the Liver Cancer-RIKEN JP) was collected from the ICGC database (<https://dcc.icgc.org/>). GSE97172 dataset was downloaded from GEO database (<https://www.ncbi.nlm.nih.gov/gds/>). Similarly, the raw data was preprocessed using R software.

2.6. KEGG (Kyoto Encyclopedia of Genes and Genomes) Pathway and GO (Gene Ontology) Enrichment Analyses. Briefly, GO and KEGG pathway enrichment analyses were carried out

using the DAVID platform (<https://david.ncicrf.gov/>) [26]. The GO analysis terms contain molecular function (MF), cellular component (CC), and biological process (BP). The GO enrichment results and KEGG pathways were visualized through the “GPlot package” in R software. We used $p < 0.05$ as the threshold for statistical significance.

2.7. PPI (Protein-Protein Interaction) Network Construction and Key Modules Identification. The PPI network of the differentially expressed genes was established through the STRING database (<http://www.string-db.org/>) [27]. The results gained by STRING database were further analyzed and visualized using Cytoscape 3.7.1 software. The key modules were discovered using Molecular Complex Detection (MCODE) plug-in based on MCODE score and node counts.

2.8. RNFs-Based Prognostic Model Construction. We performed univariate Cox regression analysis to identify the prognosis-related RNF genes using the “survival” package in R software. $p < 0.05$ was used as the statistically significant. Lasso Cox regression analyses were further performed for uncovering prognostic signatures using the “glmnet” package in R software. The risk score for each sample was calculated according to RNFs expression (Exp_i) and coefficient value (β_i): Risk score = $\exp(0.20 \cdot \text{RNF220} + 0.33 \cdot \text{RNF25} + 0.04 \cdot \text{TRIM25} + 0.11 \cdot \text{BMI1} + 0.057 \cdot \text{RNF216P1} + 0.007 \cdot \text{RNF115} + 0.019 \cdot \text{TRAIP} + 0.12 \cdot \text{RNF2} + 0.039 \cdot \text{RNF157} + 0.14 \cdot \text{RNF145} + 0.21 \cdot \text{RNF19B})$.

According to the median of risk score values, HCC patients were divided into high-risk and low-risk groups for the subsequent analyses. The “survival” package was utilized to calculate the differences of overall survival (OS) time between the two groups. Besides, the ROC curve analysis was also performed to evaluate the prognostic capability of this model using the “survivalROC” package in R software.

2.9. Genomic Analysis and Drug Prediction for Prognostic RNFs. The mutation of RNF genes was analyzed through cBioPortal (<https://www.cbioportal.org/>), which is a public platform used for analyzing and visualizing the cancer genomics datasets. All data for RNFs-related drugs were analyzed through PharmacoDB (<https://pharmacodb.pmgonomics.ca/>) [28].

2.10. Detection of the Risk Genes in Protein Level. The protein expression level of these risk genes was evaluated through the Human Protein Atlas (HPA) database for further verifying the transcriptional level of the related genes (<https://www.proteinatlas.org/>).

2.11. Statistical Analyses. Statistical analyses were conducted using the SPSS software (Inc., Chicago, IL) or R software. Univariate and multivariate Cox analyses were utilized to identify independent prognostic factors. The overall survival (OS) and disease-free survival (DFS) curves were calculated using Kaplan-Meier analysis, and the statistical significance between different groups was calculated by log-rank test. A Student’s *t*-test was used to calculate the significance between two groups of the indicated samples. $p < 0.05$ was used as statistically significant.

3. Results

3.1. The Differently Expressed RNFs Were Identified between Hepatic Normal and Tumorous Tissues. To study the roles of RNFs in HCC, we downloaded the transcriptomic file from the TCGA-LIHC dataset consisting of 50 normal tissue samples and 374 HCC samples. Then, we screened the differently expressed RNFs using the cut-off values of $\text{FDR} < 0.05$ and $|\log_2 \text{FC}| \geq 1$. Totally, 105 upregulated and 2 downregulated RNF genes were uncovered (Figure 1(a)). The expression profile of these identified RNFs is described in Figure 1(b).

3.2. GO and KEGG Pathway Analyses Were Performed with the Differently Expressed RNFs. To analyze the function of these identified RNFs, we conducted GO enrichment and KEGG pathway analyses. GO analyses categorized RNFs into three groups including GOBP, GOCC, and GOMF. The top 10 enriched GOBP, GOCC, and GOMF are presented in Figures 2(a)–2(c), respectively. Based on the GO analyses, differently expressed RNFs were mainly involved in protein polyubiquitination, ubiquitin ligase complex, and zinc-ion binding pathways. Furthermore, KEGG analysis suggest that the top 5 enriched pathways were “ubiquitin mediated proteolysis”, “Notch signaling pathway”, “signaling pathways regulating pluripotency of stem cells”, “pathways in cancer”, and “protein processing in endoplasmic reticulum” (Figure 2(d)). These pathways are tightly associated with protein ubiquitination and tumorigenesis. Thus, these enrichment analyses of these differently expressed RNFs in HCC revealed that the alterations of ubiquitination network caused by these RNFs contribute to HCC development and progression.

3.3. The PPI Network Was Constructed Using the Differently Expressed RNFs. Next, we explored the critical protein association networks of these 107 RNFs. STRING platform were utilized to establish PPI network for exploring the interactions among these RNFs. We obtained 103 nodes and 548 edges using a p value of $\text{PPI concentration} < 1.0e-16$ as selection criteria. The top two enriched clusters in the PPI network were identified using the Cytoscape with MCODE plug-in (Figures 2(e) and 2(f)). The function of each cluster was next analyzed by pathway enrichment analysis. The results revealed that Module 1 was mainly involved in ubiquitin-mediated proteolysis. Module 2 mainly participated in regulating pluripotency of stem cells and ER (endoplasmic reticulum)-related protein processing. Thus, the PPI analysis confirmed that RNFs play an important role in protein ubiquitination, which is tightly associated with HCC progression.

3.4. Recognition of Prognosis-Related RNFs and Establishment of Prognostic Model in HCC. To explore the prognostic value of the differently expressed RNFs, the univariate Cox regression analyses were conducted using corresponding TCGA clinical data. As shown in Supplementary Figure S1, 29 candidate RNFs were found to be associated with the overall survival (OS) of HCC patients. Moreover, we performed Lasso Cox regression analysis to select the prognostic RNFs for constructing prognostic model (Figures 3(a) and 3(b)). According to the integrated prognostic relevance, 11 RNF genes (RNF220, RNF25, TRIM25, BMI1, RNF216P1,




FIGURE 1: The differentially expressed RNFs were identified between hepatic normal and tumor tissues. (a) Volcano plot displaying RNFs. The upregulated RNF is shown in red and downregulated RNF is shown in green. Black means no difference. (b) Hierarchical clustering of differentially expressed RNFs is presented. The columns mean samples and the rows indicate RNFs. The green means downregulation while the red means upregulation.


RNF115, RNF2, TRAIIP, RNF157, RNF145, and RNF19B) were selected to construct a risk score model. We calculated the risk score for each patient according to expression values of 11 RNFs as follows: Risk score = $\exp(0.20 \cdot \text{RNF220} + 0.33 \cdot \text{RNF25} + 0.04 \cdot \text{TRIM25} + 0.11 \cdot \text{BMI1} + 0.057 \cdot \text{RNF216} + 0.007 \cdot \text{RNF115} + 0.019 \cdot \text{TRAIIP} + 0.12 \cdot \text{RNF2} + 0.039 \cdot \text{RNF157} + 0.14 \cdot \text{RNF145} + 0.21 \cdot \text{RNF19B})$. According to results from Lasso-penalized Cox regression, all these RNFs had positive coefficients and acted as independent prognostic factors for OS of the patients with HCC.

Based on the median of risk score values, the patients with HCC were divided into low-risk and high-risk groups. Compared with the patients in the low-risk, HCC patients in high-risk group had a worse outcome by OS analysis in TCGA cohort (Figure 3(c)). In addition, we employed the ROC analysis to evaluate the prognostic ability of the risk model. As shown in Figure 3(d), the areas under the ROC curve (AUC) of our model were 0.778, 0.675 and 0.698 at 1 year, 3 years, and 5 years, respectively, using the data of TCGA cohort. This result suggests that the risk score model is more accurate in the short-term follow-up. Moreover, the risk scores of these patients were ranked and exhibited according to risk score (Figure 3(e)). The survival status of each HCC patient in TCGA-LIHC cohort was shown in Figure 3(f). Consistently, there were shorter OS time and higher mortality rates in the patients with high-risk than those in the low-risk (Figure 3(f)). These data confirmed the


utility of our risk score model in evaluating the prognosis of HCC patients. Additionally, the expression profiles of these prognosis-related RNFs between the two groups were presented in Figure 3(g). The result revealed that all the prognostic RNFs were upregulated in the HCC patients with high-risk.

3.5. Independent Prognostic Value of the Risk Score Model Was Analyzed in HCC. Subsequently, we performed univariate Cox regression analysis to explore the relations of clinic-pathological characteristics and the risk score with prognosis in the TCGA-LIHC patients. As shown in Figure 4(a), tumor stage and risk score were tightly related to the overall survival. The following multivariate Cox regression analysis further confirmed that risk score and TNM stage were two independent prognostic factors of survival for patients with HCC (Figure 4(b)). Next, we compared the AUC values of these clinical factors at 1-year, 3-year, or 5-year. The results indicated that our model more precisely forecasted 1-year OS rate compared to TNM stage (Figures 4(c)–4(e)).


3.6. The Prognostic Signature Was Validated for OS Prediction in ICGC Cohort. For confirming the predictive power of our model, HCC patients with clinical information from the ICGC were enrolled as a validation cohort. Based on the expression level of the 11 RNFs, the risk score of each patient were calculated using the risk score formula. Then, we used the median




(a)




(b)



(c)



(d)



(e)

FIGURE 2: Continued.




FIGURE 2: GO enrichment, KEGG pathway, and PPI network analyses of differentially expressed RNFs. (a–c) The top 10 items enriched GOBP (a), GOCC (b), and GOMF (c) in GO analyses. (d) The top seven enriched pathways are shown in KEGG analysis. (e) Module 1. MCODE score = 28.00, Nodes = 28, Edges = 378. (f) Module 2. MCODE score = 4.67, Nodes = 10, Edges = 21.

of risk score values as cut-off and subdivided the patients into high-risk and low-risk groups. We analyzed the difference of survival of these two groups by survival analysis and found that patients with high-risk had a shorter OS compared with the patients with low risk (Figure 4(f)). Then, the risk scores of these HCC patients were ranked and exhibited in Figure 4(g). The survival status of each ICGC-HCC patient was estimated. As shown in Figure 4(h), there were shorter OS time and higher mortality rates in the patients with high-risk than those in the low-risk group. ROC curve was further calculated and the AUC for the OS model at 1-year and 3-year were 0.766 and 0.662, respectively, in ICGC cohort (Figure 4(i)). Together, these data indicated that our risk score model is useful for estimating the outcome of ICGC HCC patients. Together, our risk score model based on RNF gene expression precisely predicts the prognosis of HCC patients.

3.7. The Relationships between the Prognosis-Related RNFs and Clinicopathological Features Were Analyzed. Next, we explored the associations of these prognostic RNFs and clinicopathological features, including TNM stage and tumor grade. As shown in Figure 5(a), nine RNFs (RNF220, RNF25, TRIM25, RNF216P1, RNF115, TRAIP, RNF2, RNF157, and RNF145) were found to be upregulated in HCC patients with advanced grade ($p < 0.05$). Moreover, six RNFs were increased in patients with advanced stage, including RNF220, BMI1, RNF216P1, TRAIP, RNF145, and RNF19B (Figure 5(b)). Importantly, the risk scores of patients with advanced grade or stage are much higher, indicating that our prognostic model was associated with both tumor grade and TNM stage.

The genetic changes of these RNFs were further determined using the cBioPortal website. Mainly, the genetic alterations of these RNF genes include truncating mutation, missense mutation, deep deletion, structural variant, and amplification. The top 5 most significantly altered genes are RNF115, RNF2, RNF157, TRIM25, and TRAIP in HCC samples (Figure 5(c)).

3.8. The Protein Levels of Prognostic RNFs Expression Were Analyzed through the HPA Database. We next assessed the protein levels of the 11 prognostic RNFs through the HPA database. We found that eight RNFs including RNF220, RNF25, TRIM25, BMI1, RNF115, TRAIP, RNF157, and RNF19B were

overexpressed in HCC cells compared to normal cells by immunohistochemistry (IHC) staining (Figures 6(a)–6(h)). Finally, the staining of RNF2 and RNF145 proteins was missing and needs further analysis.

3.9. Functional Study of the Roles of BMI1 in HCC Cells. Due to the prognostic values of the 11 RNFs for HCC patients, we next explored the potential drugs for these RNFs through the PharmacDB database. Only BMI1 was identified as small molecule targets among these prognostic RNFs. As a core element of polycomb repressive complex 1 (PRC1), BMI1 has been found to be associated with various human cancers and become an attractive therapeutic target. One of the specific BMI1 inhibitors, PTC-209, displays high potency in repressing the growth of some types of cancer cells [29, 30]. However, it is unknown whether PTC-209 shows the potential capability in anti-HCC therapy.

Survival analysis using TCGA-LIHC cohort revealed that the high BMI1 expression was associated with shorter OS and DFS in the HCC patients (Figure 7(a)). Moreover, the expression of BMI1 on 18 paired cancerous and matched non-cancerous sections of HCC tissues from our center was evaluated by immunoblotting. As shown in Figure 7(b), BMI1 was upregulated in cancerous tissues compared to peritumoral tissues. Importantly, the MTS assay showed that the proliferation of HCC cells was significantly repressed by PTC-209 treatment (Figures 7(c)–7(e)). To further confirm our results, we randomly selected SMMC-7721 and HepG2 cells to perform colony formation assay. Consistently, colony formation of HCC cells was significantly decreased upon PTC-209 treatment (Figure 7(f)). Together, these data indicated that PTC-209 inhibits HCC cell proliferation and growth *in vitro*.

To explore the mechanisms underlying BMI1-induced HCC progression, we analyzed the differentially expressed genes in liver tissues from BMI1-knockout mice (GSE97172). As shown in Figure 7(g), 624 genes were found to be differentially expressed. KEGG analysis suggested that immune system-related pathways were significantly altered upon BMI1 loss (Figure 7(h)). These results indicated that BMI1 might be involved in regulating tumor immune micro-environment. Tumor-infiltrating lymphocytes can be used as an independent indicator of the survival and sentinel lymph node status in human cancers [31]. Therefore, we analyzed




FIGURE 3: Continued.




FIGURE 3: The risk score model was established based on prognostic RNFs using the TCGA HCC cohort. (a) Each curve indicates an *RNF* gene and the best lambda was computed to minimize mean cross-validated error. (b) The proportional hazards model was employed for cross-validation to select tuning parameter. (c) Kaplan-Meier analysis of TCGA-LIHC patients based on risk score. (d) Time-dependent ROC curves were established to estimate OS according to the risk score. (e) HCC patients were subdivided into high-risk and low-risk groups using the median of risk scores as cut-off. (f) Scatter plots displayed the associations of risk score status with survival outcome in TCGA HCC patients. (g) The heat map displayed the expression levels of prognostic RNFs in each HCC patient from TCGA cohort. The red represents increased expression and the green indicates decreased expression.

whether BMI1 expression was correlated with the infiltration of immune cells in HCC using TIMER website. The results show that BMI1 expression has positive correlations with CD8⁺ T cell, CD4⁺ T cell, neutrophil, B cell, and dendritic cell infiltration levels while BMI1 expression is negatively associated with natural killer cell infiltration level (Figure 7(i)). We also assessed the correlation between BMI1 expression and immune checkpoint-related molecules, including PD-L1, Galectin 9, HVEM, and IDO1, all of which are important marker genes for cancer immune therapy [32]. As shown in Figure 7(j), there were positive correlations between BMI1 expression level and the expression levels of these four marker genes. Together, these data suggest that BMI1 might be a novel target in HCC immunotherapy.

4. Discussion

Metastasis and recurrence after resection are common for HCC, which causes treatment failure and cancer-related death [33–35]. Development of prognostic assessment system will be favorable for follow-up after treatment, in order to attenuate tumor progression caused by metastasis or relapse, especially in patients with high-risk. Clinically, prognostic evaluation

includes tumor status, cancer-related symptoms, and liver function of the patient [36]. Recently, with the improvement of high-throughput technologies, it is possible to develop molecular typing for cancer diagnosis and treatment. In the present study, we identified RNF-based molecular biomarkers and constructed a risk score model to forecast outcomes of HCC patients using TCGA-LIHC cohort. We further validated the risk model using ICGC-LIHC dataset. Moreover, we also explored the roles of a typical prognostic RNFs and BMI1, in HCC progression. Recently, some latent biomarkers and therapeutic targets have been identified for HCC by bioinformatics strategies. The eleven RNA-binding proteins (RBPs) were screened to construct a prognostic model for indicating overall outcomes of HCC patients [37]. A four-gene metabolic signature predicting OS for HCC was built [38]. The immune-related gene prognostic signature for HCC was also constructed [39]. Currently, the prognosis model based on the RNFs of HCC has not been reported. Thus, our study determines the prognostic values of RNF genes in HCC and provides a new idea for HCC diagnosis and treatment.

Dysregulation of some RNFs leads to abnormal ubiquitination of the important proteins in tumor cells and drives tumorigenesis, including HCC [40]. Here, we aimed at studying the




FIGURE 4: Continued.




FIGURE 4: Validation of the reliability of the risk score model. (a) Univariate Cox regression analysis of the indicators. (b) Multivariate Cox regression analysis of the indicators. (c–e) Time-dependent ROC curves were used to analyze the predicting ability of the indicated factors in the TCGA HCC cohort. (f) Kaplan-Meier curve of ICGC patients was analyzed according to the risk score. (g) ICGC-LIHC patients were divided into high-risk and low-risk groups based on the median of risk score. (h) Scatter plots displayed the relationships of risk score status with the survival outcome in the ICGC HCC patients. (i) Time-dependent ROC curves were calculated according to risk scores in the ICGC HCC cohort.

universal roles of RNF genes in forecasting OS of HCC patients. Through screening differentially expressed genes between HCC and normal tissues, total 107 RNFs were identified as differentially expressed RNFs using TCGA cohort. Then, GO enrichment and KEGG pathway analyses revealed that the differentially expressed RNFs were greatly involved in ubiquitin-mediated proteolysis. We uncovered 29 prognosis-associated candidate RNFs by univariate Cox regression analysis. With Lasso Cox regression, eleven RNFs genes (RNF220, RNF25, TRIM25, BMI1, RNF216P1, RNF115, RNF2, TRAIP, RNF157, RNF145, and RNF19B) were identified to construct a risk score model. We confirmed the stability and reliability of this model using ICGC data as the validation set. The results suggested that the model is accurate for distinguishing HCC patients with different survival outcomes. Univariate and multivariate analyses further confirmed that this prognosis model could independently indicate overall prognosis of patients with HCC. ROC curve also manifested that our model based on the 11 RNFs had a good predictive ability. These results suggest that our risk model might be applied to screen high-risk patients for personalized detection or follow-up.

Among the eleven RNF genes, the majority (RNF220, RNF25, TRIM25, RNF115, BMI1, TRAIP, RNF2, RNF157,

RNF145, and RNF19B) have been reported to function in ubiquitination and play roles in tumorigenesis. RNF220 is associated with progression of leukemia or medulloblastoma [41, 42]. RNF25 upregulates gefitinib resistance via promoting ERK reactivation in EGFR-mutant NSCLC cells [43]. TRIM25 takes part in tumor growth, metastasis, and chemoresistance with its ubiquitin ligase activities [18, 44]. RNF115 is correlated with the prognosis of patients with lung adenocarcinoma or invasive breast cancer [45, 46]. As a master regulator of DNA repair, dysfunction of TRAIP is associated with tumor development and progression [47, 48]. Overexpression of RNF2 is positively correlated with progression of many cancers, including HCC, melanoma, pancreatic cancer, and gastric cancer [49].

BMI1 is a core element of the PRC1 complex which mediates gene silencing via monoubiquitination of histone H2A. The polycomb group (PcG) proteins encoding transcriptional repressors are indispensable for maintenance of stem cell pluripotency [50, 51]. The PcG proteins form multimeric protein complexes to regulate transcription of development-related genes, which are called as polycomb repressive complexes (PRCs) [52]. Currently, two major PRCs have been identified, PRC1 and PRC2, both of which modify chromatin to stably




FIGURE 5: Continued.



FIGURE 5: The relevance between prognostic RNFs and clinicopathologic features was analyzed. (a) The association of these prognostic RNFs with tumor grade was evaluated. (b) The relationship between prognostic RNFs and tumor stage was analyzed. (c) OncoPrint for each prognostic RNF gene.




FIGURE 6: The protein levels of the prognostic RNFs were evaluated in the HPA database. (a-h) IHC staining of prognostic RNF in HCC tumor tissues and normal liver tissues.




FIGURE 7: Continued.




FIGURE 7: Functional studies of BMI1 in HCC progression. (a) Kaplan-Meier survival analysis for overall survival and disease-free survival of the TCGA-LIHC patients based on BMI1 mRNA level. (b) Western blot analysis of BMI1 expression in 18 individual paired HCC tissues. (c-e) Cell proliferation assay was performed in HCC cells after PTC-209 treatment. (f) Colony formation assay was conducted in HCC cells treated with PTC-209. (**** $p < 0.0001$) (g) Volcano plot for DEGs between BMI1 wild-type and BMI1 knockout mice liver tissues using GSE97172 dataset. (h) KEGG pathway analysis for DEGs identified in (g). (i) The correlation of BMI1 expression with immune infiltration level was analyzed in HCC tissues. (j) Coexpression analysis between the expression level of PD-L1, Galectin 9, HVEM, IDO, and BMI1 using TCGA-LIHC data.

silence transcription at targeted genes [53]. As an E3 ubiquitin ligase, BMI1 works with its partners to catalyze the PcG-dependent ubiquitination of histone H2A in order to modulate transcription [54]. In tumorigenesis, BMI1 plays important roles in promoting cancer stemness, leading to tumor metastasis, recurrence, and drug resistance [55]. Thus, the development of small molecule inhibitors against BMI1 will offer potential opportunities for cancer treatment. PTC-209, as an important inhibitor of BMI1, downregulated BMI1 by reducing mRNA level. PTC-209 exerts inhibitory effects for several cancers, such as breast cancer, non-small cell lung cancer, and acute myeloid leukemia [30, 56, 57]. However, the effect of PTC-209 in anti-HCC is unclear. Here, we found that BMI1 is critical in constructing the risk score model. Our further studies show that BMI1 is upregulated in HCC tissues and the upregulation of BMI1 is associated with poor outcomes of HCC patients, confirming that BMI1 plays important roles in hepatocarcinogenesis. Importantly, we found that PTC-209 significantly inhibits HCC cell growth and proliferation. Thus, our results identify the inhibition of BMI1 as a potential strategy for HCC treatment. We also analyzed the downstream targets of BMI1 by comparing expression profiles of BMI1 wild-type and BMI1-knockout tissues. Strikingly, we found that these targets are enriched in immune-related events. Moreover, the expression of BMI1 correlates with immune cells' infiltration level in HCC, suggesting that BMI1 might be a novel target for improving HCC immune therapy.

Recently, the proteolysis targeting chimeras (PROTACs) technology attracts growing attention of scientific institutes and pharmaceutical companies [58]. PROTACs are designed based on the ubiquitin-proteasome system to induce the degradation of targeted protein. Briefly, the ligands in PROTACs combine with E3 ligase and the targeted protein, respectively, and the linker connects the two ligands and pulls them closer together. PROTACs show positive results for degrading the “undrugable” oncoproteins which lack of binding pockets by small molecule inhibitors [59]. The PROTACs-related new drugs are tested in clinical trials for cancer therapy [59]. Due to the importance of RNF protein-related ubiquitination in tumorigenesis, it is possible that the PROTACs based on RNFs could be useful for cancer treatment. This will be further studied in the future.

In addition, some limitations should be addressed in the future to increase the possibility of our risk model in HCC diagnosis. First, our study was a retrospective study based on the public datasets. It will be better to validate our model using data from prospective clinical trials. Second, the detailed molecular mechanisms of the RNF genes in hepatocellular carcinogenesis are not fully understood. Moreover, discoveries of effective drugs for targeting prognostic RNFs will be more helpful for HCC treatment by *in vivo* experiments and clinical trials. In the future study, we will try to address this issue in subsequent studies.

In summary, using a systematic and comprehensive biomarker discovery and validation approach, we uncovered that an RNF-related gene signature could act as a prognostic indicator for evaluating prognosis of HCC patients and guide HCC treatment. We also identified that BMI1 is tightly associated with HCC progression, which might be a new therapeutic target for HCC.

Data Availability

All data generated or analyzed during this study are included in this article and its supplementary files. The analyzed data during the current study are available from the corresponding authors on reasonable request.

Ethical Approval

The study protocol was approved by the Ethics Committee of Peking University Cancer Hospital.

Consent

All the authors agree to the content of the paper and their being listed as a coauthor of the paper. Written informed consent was acquired from all the patients.

Conflicts of Interest

The authors declare that there are no conflicts of interest.

Authors' Contributions

Xiaofeng Liu worked on conception and designs. Chunfeng Zhang and Xiaofeng Liu worked on bioinformatic analysis. Chunfeng Zhang worked on experiments. Chunfeng Zhang, Min Lu, Yang Yang, Muhua Chen, Chenyu Hu, and Kun Wang worked on data collection. Xiaojuan Du, Xiaofeng Liu, and Bao-cai Xing worked on manuscript preparation and supervision.

Acknowledgments

This work was supported by the grants from the National Natural Science Foundation of China (Grant No. 81802305, 31971192, and 81874143), the Beijing Natural Science Foundation (Grant No. 7192035), and the Science Foundation of Peking University Cancer Hospital (2020-1).

Supplementary Materials

Supplementary Figure S1: univariate Cox regression analysis of OS for each prognosis-associated candidate RNF gene. (*Supplementary Materials*)

References

- [1] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” *CA: a Cancer Journal for Clinicians*, vol. 68, no. 6, pp. 394–424, 2018.
- [2] M. Chen, C. Zhang, W. Liu, X. Du, X. Liu, and B. Xing, “Long noncoding RNA LINC01234 promotes hepatocellular carcinoma progression through orchestrating aspartate metabolic reprogramming,” *Molecular Therapy*, vol. 30, no. 6, pp. 2354–2369, 2022.
- [3] A. Koulouris, C. Tsagkaris, V. Spyrou, E. Pappa, A. Troullinou, and M. Nikolaou, “Hepatocellular carcinoma: an overview of the changing landscape of treatment options,” *Journal of Hepatocellular Carcinoma*, vol. 8, pp. 387–401, 2021.

- [4] S. Li and M. Mao, "Next generation sequencing reveals genetic landscape of hepatocellular carcinomas," *Cancer Letters*, vol. 340, no. 2, pp. 247–253, 2013.
- [5] Q. Li, X. Liu, K. Jin et al., "NAT10 is upregulated in hepatocellular carcinoma and enhances mutant p53 activity," *BMC Cancer*, vol. 17, no. 1, p. 605, 2017.
- [6] J. M. Llovet, R. Montal, D. Sia, and R. S. Finn, "Molecular therapies and precision medicine for hepatocellular carcinoma," *Nature Reviews Clinical Oncology*, vol. 15, no. 10, pp. 599–616, 2018.
- [7] P. H. D. Nguyen, S. Ma, C. Z. J. Phua et al., "Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma," *Nature Communications*, vol. 12, no. 1, p. 227, 2021.
- [8] X. Liu, Y. Tan, C. Zhang et al., "NAT10 regulates p53 activation through acetylating p53 at K120 and ubiquitinating Mdm2," *EMBO Reports*, vol. 17, no. 3, pp. 349–366, 2016.
- [9] Y. Wang, J. Dai, Y. Zeng, J. Guo, and J. Lan, "E3 ubiquitin ligases in breast cancer metastasis: a systematic review of pathogenic functions and clinical implications," *Frontiers in Oncology*, vol. 11, article 752604, 2021.
- [10] C. W. Fhu and A. Ali, "Dysregulation of the ubiquitin proteasome system in human malignancies: a window for therapeutic intervention," *Cancers (Basel)*, vol. 13, no. 7, p. 1513, 2021.
- [11] I. Dikic, S. Wakatsuki, and K. J. Walters, "Ubiquitin-binding domains - from structures to functions," *Nature Reviews Molecular Cell Biology*, vol. 10, no. 10, pp. 659–671, 2009.
- [12] C. E. Berndsen and C. Wolberger, "New insights into ubiquitin E3 ligase mechanism," *Nature Structural & Molecular Biology*, vol. 21, no. 4, pp. 301–307, 2014.
- [13] M. B. Metzger, V. A. Hristova, and A. M. Weissman, "HECT and RING finger families of E3 ubiquitin ligases at a glance," *Journal of Cell Science*, vol. 125, no. 3, pp. 531–537, 2012.
- [14] T. Okamoto, K. Imaizumi, and M. Kaneko, "The Role of Tissue-Specific Ubiquitin Ligases, RNF183, RNF186, RNF182 and RNF152, in Disease and Biological Function," *International Journal of Molecular Sciences*, vol. 21, no. 11, 2020.
- [15] A. M. Jaworska, N. A. Wlodarczyk, A. Mackiewicz, and P. Czerwinska, "The role of TRIM family proteins in the regulation of cancer stem cell self-renewal," *Stem Cells*, vol. 38, no. 2, pp. 165–173, 2020.
- [16] J. Fu, L. Liao, K. S. Balaji, C. Wei, J. Kim, and J. Peng, "Epigenetic modification and a role for the E3 ligase RNF40 in cancer development and metastasis," *Oncogene*, vol. 40, no. 3, pp. 465–474, 2021.
- [17] A. Mattioni, L. Castagnoli, and E. Santonico, "RNF11 at the Crossroads of Protein Ubiquitination," *Biomolecules*, vol. 10, no. 11, 2020.
- [18] Y. Liu, S. Tao, L. Liao et al., "TRIM25 promotes the cell survival and growth of hepatocellular carcinoma through targeting Keap1-Nrf2 pathway," *Nature Communications*, vol. 11, no. 1, p. 348, 2020.
- [19] C. Qu and Y. Q. Qu, "Down-regulation of salt-inducible kinase 1 (SIK1) is mediated by RNF2 in hepatocarcinogenesis," *Oncotarget*, vol. 8, no. 2, pp. 3144–3155, 2017.
- [20] C. C. So, S. Ramachandran, and A. Martin, "E3 Ubiquitin ligases RNF20 and RNF40 are required for double-stranded break (DSB) repair: evidence for monoubiquitination of histone H2B lysine 120 as a novel axis of DSB signaling and repair," *Molecular and Cellular Biology*, vol. 39, no. 8, p. 39, 2019.
- [21] X. Y. Zheng, K. Chen, X. L. Liu, Y. Pan, and H. Liu, "High RNF40 expression indicates poor prognosis of hepatocellular carcinoma," *International Journal of Clinical and Experimental Pathology*, vol. 11, no. 5, pp. 2901–2906, 2018.
- [22] C. Zhang, C. Hu, K. Su et al., "The integrative analysis of thrombospondin family genes in pan-cancer reveals that THBS2 facilitates gastrointestinal cancer metastasis," *Journal of Oncology*, vol. 2021, Article ID 4405491, pp. 1–19, 2021.
- [23] X. Liu, D. Xu, Z. Liu et al., "THBS1 facilitates colorectal liver metastasis through enhancing epithelial-mesenchymal transition," *Clinical & Translational Oncology*, vol. 22, no. 10, pp. 1730–1740, 2020.
- [24] X. F. Liu, K. Q. Su, X. Y. Sun et al., "Sec62 promotes stemness and chemoresistance of human colorectal cancer through activating Wnt/beta-catenin pathway," *Journal of Experimental & Clinical Cancer Research*, vol. 40, no. 1, 2021.
- [25] Z. Tang, C. Li, B. Kang, G. Gao, C. Li, and Z. Zhang, "GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses," *Nucleic Acids Research*, vol. 45, no. W1, pp. W98–W102, 2017.
- [26] D. W. Huang, B. T. Sherman, and R. A. Lempicki, "Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists," *Nucleic Acids Research*, vol. 37, no. 1, pp. 1–13, 2009.
- [27] D. Szklarczyk, A. L. Gable, D. Lyon et al., "STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets," *Nucleic Acids Research*, vol. 47, no. D1, pp. D607–D613, 2019.
- [28] P. Smirnov, V. Kofia, A. Maru et al., "PharmacoDB: an integrative database for mining in vitro anticancer drug screening studies," *Nucleic Acids Research*, vol. 46, no. D1, pp. D994–D1002, 2018.
- [29] J. H. Wang, Y. J. Xing, Y. Y. Wang et al., "A novel BMI-1 inhibitor QW24 for the treatment of stem-like colorectal cancer," *Journal of Experimental & Clinical Cancer Research*, vol. 38, no. 1, 2019.
- [30] H. T. Shen, P. J. Chien, S. H. Chen et al., "BMI1-mediated pemetrexed resistance in non-small cell lung cancer cells is associated with increased SP1 activation and cancer stemness," *Cancers (Basel)*, vol. 12, no. 8, p. 2069, 2020.
- [31] F. Azimi, R. A. Scolyer, P. Rumcheva et al., "Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma," *Journal of Clinical Oncology*, vol. 30, no. 21, pp. 2678–2683, 2012.
- [32] K. Sideras, K. Biermann, K. Yap et al., "Tumor cell expression of immune inhibitory molecules and tumor-infiltrating lymphocyte count predict cancer-specific survival in pancreatic and ampullary cancer," *International Journal of Cancer*, vol. 141, no. 3, pp. 572–582, 2017.
- [33] D. Xu, X. Liu, L. Wang, and B. Xing, "Hepatectomy plus adjuvant transcatheter arterial chemoembolization improves the survival rate of patients with multicentric occurrence of hepatocellular carcinoma," *Oncology Letters*, vol. 16, no. 5, pp. 5882–5890, 2018.
- [34] Y. Tan, J. Zheng, X. Liu et al., "Loss of nucleolar localization of NAT10 promotes cell migration and invasion in hepatocellular carcinoma," *Biochemical and Biophysical Research Communications*, vol. 499, no. 4, pp. 1032–1038, 2018.

- [35] Y. Yang, P. Ren, X. Liu et al., “PPP1R26 drives hepatocellular carcinoma progression by controlling glycolysis and epithelial-mesenchymal transition,” *Journal of Experimental & Clinical Cancer Research*, vol. 41, no. 1, p. 101, 2022.
- [36] J. Bruix, M. Reig, and M. Sherman, “Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma,” *Gastroenterology*, vol. 150, no. 4, pp. 835–853, 2016.
- [37] L. Wang, Z. Zhang, Y. Li, Y. Wan, and B. Xing, “Integrated bioinformatic analysis of RNA binding proteins in hepatocellular carcinoma,” *Aging (Albany NY)*, vol. 13, no. 2, pp. 2480–2505, 2020.
- [38] G. M. Liu, W. X. Xie, C. Y. Zhang, and J. W. Xu, “Identification of a four-gene metabolic signature predicting overall survival for hepatocellular carcinoma,” *Journal of Cellular Physiology*, vol. 235, no. 2, pp. 1624–1636, 2020.
- [39] W. B. Chen, M. L. Ou, O. G. Tang, Y. Dai, and W. Du, “Identification and validation of immune-related gene prognostic signature for hepatocellular carcinoma,” *Journal of Immunology Research*, vol. 2020, Article ID 5494858, 14 pages, 2020.
- [40] J. Yin, J. M. Zhu, and X. Z. Shen, “The role and therapeutic implications of RING-finger E3 ubiquitin ligases in hepatocellular carcinoma,” *International Journal of Cancer*, vol. 136, no. 2, pp. 249–257, 2015.
- [41] P. C. Ma, T. An, L. Zhu et al., “RNF220 is required for cerebellum development and regulates medulloblastoma progression through epigenetic modulation of Shh signaling,” *Development*, vol. 147, no. 21, 2020.
- [42] Y. M. Pan, N. An, X. P. Deng, Q. X. Zhang, and X. Du, “RNF220 promotes the proliferation of leukaemic cells and reduces the degradation of the cyclin D1 protein through USP22,” *Blood Cells, Molecules, and Diseases*, vol. 86, article 102490, 2021.
- [43] J. H. Cho, Y. M. You, Y. I. Yeom et al., “RNF25 promotes gefitinib resistance in EGFR-mutant NSCLC cells by inducing NF- κ B-mediated ERK reactivation,” *Cell Death & Disease*, vol. 9, no. 6, p. 587, 2018.
- [44] Y. M. He, X. M. Zhou, S. Y. Jiang et al., “TRIM25 activates AKT/mTOR by inhibiting PTEN via K63-linked polyubiquitination in non-small cell lung cancer,” *Acta Pharmacologica Sinica*, vol. 43, no. 3, pp. 681–691, 2022.
- [45] A. M. Burger, Y. G. Gao, Y. Amemiya et al., “A novel RING-type ubiquitin ligase breast cancer-associated gene 2 correlates with outcome in invasive breast cancer,” *Cancer Research*, vol. 65, no. 22, pp. 10401–10412, 2005.
- [46] X. T. Wu, Y. H. Wang, X. Y. Cai et al., “RNF115 promotes lung adenocarcinoma through Wnt/beta-catenin pathway activation by mediating APC ubiquitination,” *Cancer & Metabolism*, vol. 9, no. 1, 2021.
- [47] R. A. Wu, D. R. Semlow, A. N. Kamimae-Lanning et al., “TRAIP is a master regulator of DNA interstrand crosslink repair,” *Nature*, vol. 567, no. 7747, pp. 267–272, 2019.
- [48] M. E. Harley, O. Murina, A. Leitch et al., “TRAIP promotes DNA damage response during genome replication and is mutated in primordial dwarfism,” *Nature Genetics*, vol. 48, no. 1, pp. 36–43, 2016.
- [49] Q. Yan, B. J. Chen, S. Hu et al., “Emerging role of RNF2 in cancer: from bench to bedside,” *Journal of Cellular Physiology*, vol. 236, no. 8, pp. 5453–5465, 2021.
- [50] S. Aranda, G. Mas, and L. Di Croce, “Regulation of gene transcription by polycomb proteins,” *Science Advances*, vol. 1, no. 11, 2015.
- [51] U. Grossniklaus and R. Paro, “Transcriptional silencing by polycomb-group proteins,” *Cold Spring Harbor Perspectives in Biology*, vol. 6, no. 11, 2014.
- [52] J. A. Simon and R. E. Kingston, “Mechanisms of polycomb gene silencing: knowns and unknowns,” *Nature Reviews Molecular Cell Biology*, vol. 10, no. 10, pp. 697–708, 2009.
- [53] Z. Wang, M. D. Gearhart, Y. W. Lee et al., “A non-canonical BCOR-PRC1.1 complex represses differentiation programs in human ESCs,” *Cell Stem Cell*, vol. 22, no. 2, pp. 235–251.e9, 2018, e239.
- [54] A. Fitieh, A. J. Locke, M. Motamedi, and I. H. Ismail, “The role of polycomb group protein BMI1 in DNA repair and genomic stability,” *International Journal of Molecular Sciences*, vol. 22, no. 6, p. 2976, 2021.
- [55] H. R. Siddique and M. Saleem, “Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: preclinical and clinical evidences,” *Stem Cells*, vol. 30, no. 3, pp. 372–378, 2012.
- [56] K. Barbosa, A. Deshpande, B. R. Chen et al., “Acute myeloid leukemia driven by the CALM-AF10 fusion gene is dependent on BMI1,” *Experimental Hematology*, vol. 74, pp. 42–51.e3, 2019.
- [57] Q. Wang, Z. Li, Y. Wu et al., “Pharmacological inhibition of BMI1 by PTC-209 impaired tumor growth in head neck squamous cell carcinoma,” *Cancer Cell International*, vol. 17, no. 1, p. 107, 2017.
- [58] Z. Hu and C. M. Crews, “Recent developments in PROTAC-mediated protein degradation: from bench to clinic,” *Chem-biochem*, vol. 23, no. 2, article e202100270, 2022.
- [59] M. Lv, W. Hu, S. Zhang, L. He, C. Hu, and S. Yang, “Proteolysis-targeting chimeras: a promising technique in cancer therapy for gaining insights into tumor development,” *Cancer Letters*, vol. 539, article 215716, 2022.